17:37 , May 15, 2019 |  BC Innovations  |  Distillery Therapeutics

Taxifolin could treat cerebral amyloid angiopathy

DISEASE CATEGORY: Neurology INDICATION: Alzheimer's disease (AD) Mouse studies suggest the flavonoid natural product taxifolin could help treat cerebral amyloid angiopathy (CAA), a vascular complication of AD. In a mouse model of CAA, taxifolin decreased...
01:25 , Feb 28, 2019 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer's disease (AD) Cell culture and worm studies suggest the PTP-1B inhibitor trodusquemine could help treat AD. In human cells cultured with β amyloid 42 (Aβ 42 ), trodusquemine decreased the formation of Aβ...
00:23 , Feb 15, 2019 |  BC Innovations  |  Product R&D

A bug about Alzheimer’s

Cortexyme Inc. believes it has connected the dots between Alzheimer’s and gum disease, outlining a path from the bacteria that cause periodontitis to chronic brain infection with hallmarks of AD. But in a field that...
20:04 , Jan 25, 2019 |  BC Week In Review  |  Clinical News

Cortexyme's bacterial protease inhibitor improves AD signs in mice

Cortexyme Inc. (South San Francisco, Calif.) revealed in a Science Advances paper that lead product, COR388, slowed neurodegeneration in a mouse model of Alzheimer's disease. COR388 inhibits the Porphyromonas gingivalis -derived lysine gingipain, a protease...
23:56 , Jan 24, 2019 |  BC Extra  |  Preclinical News

Cortexyme's bacterial protease inhibitor improves AD signs in mice

Cortexyme Inc. (South San Francisco, Calif.) revealed in a Science Advances paper that lead product, COR388, slowed neurodegeneration in a mouse model of Alzheimer's disease. COR388 inhibits the Porphyromonas gingivalis -derived lysine gingipain, a protease...
13:28 , Dec 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer's disease (AD) In vitro and mouse studies identified an inhibitor of Aβ 42 polymerization that could help treat AD. In vitro screening of nine amyloid-binding compounds in polymerization assays, followed by in vitro...
22:27 , Nov 6, 2018 |  BioCentury  |  Finance

Advancing AlzeCure

Stockholm-based AlzeCure Pharma AB is planning to raise SEK200 million ($22 million) in an IPO on NASDAQ First North Premier to bring both arms of its Alzheimer’s disease portfolio to the clinic. In a prospectus...
17:50 , May 16, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD) In vitro and mouse studies suggest a peptide-based agent that captures Aβ 42 and induces autophagy could help treat AD. The “nanosweeper” agent consists of a PEGylated GKLVFF peptide that binds...
22:03 , May 10, 2018 |  BC Extra  |  Preclinical News

‘Nanosweepers’ could degrade beta amyloid to treat Alzheimer’s

Researchers at Beijing’s National Center for Nanoscience and Technology and colleagues published a paper in Nature Communications describing a self-destructive "nanosweeper" based on multifunctional peptide-polymers that improved memory deficits after capturing and degrading extracellular deposits...
17:36 , May 4, 2018 |  BC Week In Review  |  Clinical News

Merck's verubecestat reduces beta amyloid levels but fails to improve cognition, function

Data published in the New England Journal of Medicine from the discontinued Phase II/III EPOCH trial in 1,958 patients with mild to moderate Alzheimer's disease showed that verubecestat (MK-8931) from Merck & Co. Inc. (NYSE:MRK)...